Sarah Mitchell is a 42-year-old woman who presents to her GP requesting help with weight loss. She has gradually gained weight over the past 10 years, particularly since having her two children. She currently weighs 95 kg and is 165 cm tall (BMI 34.9). She has tried various diets in the past but has found it difficult to sustain weight loss. She works full-time as an administrative assistant, has little time for exercise, and often relies on convenience foods. Her blood pressure is 138/88 mmHg.
Definition: Obesity is defined as abnormal or excessive fat accumulation that presents a risk to health.
Body Mass Index (BMI) Classification:
| Classification | BMI (kg/m²) | Risk of comorbidities |
|---|---|---|
| Underweight | <18.5 | Low (but risk of other problems) |
| Normal weight | 18.5-24.9 | Average |
| Overweight | 25-29.9 | Increased |
| Obesity Class I | 30-34.9 | Moderate |
| Obesity Class II | 35-39.9 | Severe |
| Obesity Class III | ≥40 | Very severe |
Alternative measures:
Note: BMI has limitations - doesn't distinguish muscle from fat, may not be accurate for all ethnic groups, very muscular individuals, pregnant women, or elderly.
Obesity is associated with numerous health complications:
Metabolic:
Cardiovascular:
Respiratory:
Musculoskeletal:
Cancer:
Reproductive:
Psychological:
Other:
Obesity results from an imbalance between energy intake and energy expenditure. The causes are multifactorial:
Primary (Simple) Obesity (\>95% of cases):
Secondary Obesity (<5% of cases):
History:
Examination:
Baseline investigations to assess complications and cardiovascular risk:
Additional investigations if clinically indicated:
Goals of treatment:
Multimodal approach - "Three pillars":
1. Dietary modification:
2. Increased physical activity:
3. Behavioural modification:
Regular follow-up: Essential for long-term success. Monitor progress, provide support, adjust plan as needed.
Pharmacological therapy:
Consider if lifestyle interventions have failed and:
Available medications:
| Drug | Mechanism | Expected weight loss |
|---|---|---|
| Orlistat | Pancreatic lipase inhibitor - reduces fat absorption | 3-5kg over 12 months. Side effects: GI symptoms, fat-soluble vitamin deficiency |
| Liraglutide (Saxenda) | GLP-1 agonist - increases satiety | 5-10kg. Daily injection. Side effects: nausea, vomiting |
| Semaglutide (Wegovy) | GLP-1 agonist | 10-15kg. Weekly injection. Most effective currently available |
Pharmacotherapy should always be combined with lifestyle modification. Continue only if ≥5% weight loss after 3 months.
Bariatric surgery:
Consider if lifestyle and pharmacological interventions have failed and:
Surgical options:
Benefits of surgery:
Risks: Surgical complications, nutritional deficiencies, need for lifelong follow-up and supplementation.
Weight maintenance is often more challenging than weight loss. Key strategies:
Emphasize that weight management is a lifelong commitment, not a short-term diet. Small lapses are normal - the key is getting back on track quickly.
Obesity is a major public health challenge:
Prevalence:
Economic burden:
Prevention strategies:
Addressing obesity requires a coordinated, multi-sectoral approach involving healthcare, education, food industry, and government policy.